Recent Updates
Recently added Catalysts

AMG 691

Phase 1

Asthma | Small molecule | Respiratory |Amgen Inc.|Last Updated: Apr 9, 2026

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindCONTROLLEDBiomarker
Total Trials1
Total Enrollment124
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT06637371A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate AsthmaPHASE1 RECRUITING 124Oct 16, 2024Jun 7, 2027Apr 9, 202621 United States, Australia +3
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs)
Up to approximately 11 months

An adverse event (AE) is any untoward medical occurrence in a clinical study participant irrespective of a causal relationship with the study treatment. TEAEs are any event that occurred after the participant received study treatment. Serious AEs (SAEs) are defined as any untoward medical occurrence that, meet at least 1 of the following serious criteria: Immediately life-threatening, requires in-patient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect. Includes AEs of interest (AEOI), and AEs leading to discontinuation.

Secondary Endpoints
Maximum Concentration (Cmax) of AMG 691
Up to approximately 11 months
Area Under the Curve (AUC) of AMG 691
Up to approximately 11 months
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelSEQUENTIAL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Part A: Single Ascending Dose (SAD)EXPERIMENTALHealthy participants will be randomized in a 3:1 ratio to receive either AMG 691 or placebo.
Part B: Multiple Ascending Dose (MAD)EXPERIMENTALHealthy participants will be randomized in a 3:1 ratio to receive either AMG 691 or placebo.
Part C: Multiple DoseEXPERIMENTALParticipants with mild-to-moderate asthma will be randomized in a 2:1 ratio to receive either AMG 691 or placebo.
Interventions
NameTypeDescription
AMG 691DRUGSubcutaneous (SC) injection
PlaceboDRUGSC injection
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 65 Years
SexALL
Healthy VolunteersYes
Study Sites21

Inclusion Part A and B * Participants must be capable of giving informed consent and have provided informed consent. * Participants must be 18 to 65, inclusive at time of signing of informed consent. * Participants must have a Body Mass Index between 18.0 to 30 kg/m\^2 and total body weight ≥ 40 kg...

Countries:United StatesAustraliaBelgiumCanadaUnited Kingdom
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT06637371primaryCompletionDate: changed
LOWMay 24, 2026NCT06637371studyFirstPostDate: changed